Payment overview · 2025
General Payments
$77.59
4 reported records · 4 companies
Healthcare provider profile · identity verified
Richard E Blalock, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MURRAY, KY · NPI 1295723328
Verified facts
What the public records show
CMS Open Payments records show Richard E Blalock, M.D. received $77.59 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.30 | 31.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.73 | 26.7% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.14 | 22.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.42 | 19.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $77.59 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
185 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 114 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 423 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 405 | 112 |
| Omeprazole | Omeprazole | 342 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 92 |
| Gabapentin | Gabapentin | 338 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 83 |
| Losartan Potassium | Losartan Potassium | 319 | 77 |
| Lisinopril | Lisinopril | 283 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 73 |
| Alprazolam | Alprazolam | 237 | 51 |
| Glimepiride | Glimepiride | 224 | 61 |
| Metformin Hcl | Metformin Hcl | 222 | 60 |
| Methylprednisolone | Methylprednisolone | 221 | 104 |
| Furosemide | Furosemide | 187 | 54 |
| Mounjaro | Tirzepatide | 185 | 24 |
| Simvastatin | Simvastatin | 175 | 45 |
| Cefdinir | Cefdinir | 173 | 79 |
| Montelukast Sodium | Montelukast Sodium | 173 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 38 |
| Azithromycin | Azithromycin | 145 | 60 |
| Metformin Hcl Er | Metformin Hcl | 144 | 36 |
| Trazodone Hcl | Trazodone Hcl | 144 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 46 |
| Buspirone Hcl | Buspirone Hcl | 132 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 126 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 24 |
| Eliquis | Apixaban | 120 | 35 |
| Meloxicam | Meloxicam | 116 | 33 |
| Diazepam | Diazepam | 112 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 33 |
| Allopurinol | Allopurinol | 106 | 28 |
| Ozempic | Semaglutide | 106 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 26 |
| Sertraline Hcl | Sertraline Hcl | 100 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 27 |
| Finasteride | Finasteride | 95 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 25 |
| Tramadol Hcl | Tramadol Hcl | 91 | 26 |
| Carvedilol | Carvedilol | 86 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 83 | 13 |
| Spironolactone | Spironolactone | 82 | 19 |
| Amoxicillin | Amoxicillin | 81 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 20 |
| Temazepam | Temazepam | 79 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 23 |
| Ezetimibe | Ezetimibe | 73 | 18 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Xarelto | Rivaroxaban | 73 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Aripiprazole | Aripiprazole | 66 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 47 |
| Farxiga | Dapagliflozin Propanediol | 65 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 13 |
| Ondansetron Odt | Ondansetron | 64 | 26 |
| Celecoxib | Celecoxib | 58 | 15 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 15 |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Famotidine | Famotidine | 56 | 21 |
| Lorazepam | Lorazepam | 56 | 11 |
| Prednisone | Prednisone | 55 | 19 |
| Jardiance | Empagliflozin | 54 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 21 |
| Fluconazole | Fluconazole | 46 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Nystatin | Nystatin | 36 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 14 |
| Meclizine Hcl | Meclizine Hcl | 33 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 19 |
| Dutasteride | Dutasteride | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Protonix | Pantoprazole Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77.59 · 4 records | ABBVIE INC. | JARDIANCE, KISUNLA, Onyda XR, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error